BriaCell Therapeutics (BCTXW) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic treatments for breast cancer and other solid tumors. The company’s research strategy centers on harnessing the body’s immune system to recognize and attack cancer cells, with an emphasis on off-the-shelf allogeneic platforms that can be readily administered without the need for patient-specific manufacturing.

The company’s lead candidate, Bria-IMT, is derived from a human breast tumor cell line engineered to express immune-stimulatory molecules designed to trigger both innate and adaptive anti-tumor responses. Bria-IMT is currently undergoing early-phase clinical evaluation in patients with advanced, hormone receptor-positive, HER2-negative breast cancer. BriaCell is also exploring combination approaches that pair its proprietary platform with established immune checkpoint inhibitors and other agents to enhance therapeutic benefit.

Headquartered in Vancouver, British Columbia, BriaCell serves patient populations in North America and is advancing international clinical collaborations to broaden access to its investigational therapies. The company’s management team combines expertise in oncology drug development, translational research and regulatory affairs, positioning BriaCell to move its immuno-oncology candidates through clinical milestones. BriaCell continues to engage with academic and industry partners as it progresses key clinical trials and seeks to expand its pipeline of novel immunotherapeutics.

Key Stats

• Today's Range: $0.0009 to $0.0009
• 50-Day Range: $0.00 to $0.02
• 52-Week Range: $0.00 to $0.25
• Volume: N/A
• Average Volume: 92,954 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCTXW
• CIK: 1610820
• Web: N/A
• Phone: 604-921-1810
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A